Canadian Outpatient VTE Management Registry

Primary Objective: \- To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings. Secondary Objective: * To describe the demographic and clinical characteristics of patients with symptomatic VTE including characteristics of VTE, VTE risk factors and bleeding risk factors. * To assess the frequency of patient characteristics that would necessitate adjustment in the dose or duration of enoxaparin therapy, e.g. high BMI, impaired creatinine clearance, advanced age, cancer-associated VTE. * To assess the degree of adherence in clinical practice to Consensus Guidelines (ACCP/American College of chest Physician 2008) for the management of acute VTE, vis a vis: * Appropriate dosing of enoxaparin * Recommended duration of initial LMWH therapy * Adequate overlap of LMWH with vitamin K antagonists (VKA) * Recommended duration of longterm VKA * Frequency of use of LMWH monotherapy to treat cancer-related VTE * To access safety outcomes (including bleeding and recurrent VTE) * To describe the utilization of resources due to bleeding and recurrent VTE during the treatment period.